ADAR1 Capital Management »

Homology Medicines shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Homology Medicines shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Homology Medicines

Tip: Access up to 7 years of quarterly data

All positions including Homology Medicines held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Homology Medicines by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $179k 294k 0.61

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Homology Medicines

5AM Venture Management
Vanguard Group
Newtyn Management
George Kaiser Family Foundation
ADAR1 Capital Management
Bank of America Corporation
Tudor Investment Corporation
Citadel Advisors
Barclays
Franklin Resources
American Investment Services
Virtu Financial
Schechter Investment Advisors
Goldman Sachs Group
Jane Street

View all funds holding Homology Medicines